SKYEPHARMA PLC - AGM RESULTS LONDON, UK, 21 May 2008 - SkyePharma PLC (LSE :SKP ) announces the results of the voting by shareholders at the Annual General Meeting held earlier today. All resolutions were passed on a show of hands. Two copies of all resolutions passed will be submitted later today to the UK Listing Authority's Document Viewing Facility which is situated at. 25 The North Colonnade Canary Wharf London E14 5HS Full details of the proxy voting will be available on our website (www.skyepharma.com) later today. For further information please contact: SkyePharma PLC Frank Condella, Chief Executive Officer Ken Cunningham, Chief Operating Officer +44 207 491 1777 Peter Grant, Finance Director Financial Dynamics (London enquiries) David Yates / Deborah Scott +44 207 831 3113 Trout Group (USA enquiries) Christine Labaree / Seth Lewis +1 617 583 1308 About SkyePharma PLC Using its proprietary drug delivery technologies, SkyePharma develops new formulations of existing products to provide a clinical advantage and life-cycle extension. The Group has twelve approved products in the areas of oral, inhalation and topical delivery. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit www.skyepharma.com. This information is provided by RNS The company news service from the London Stock Exchange END
Contact Information: Contacts: RNS Customer Services 0044-207797-4400 http://www.rns.com